423 related articles for article (PubMed ID: 19709449)
1. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
Poon E; Harris AL; Ashcroft M
Expert Rev Mol Med; 2009 Aug; 11():e26. PubMed ID: 19709449
[TBL] [Abstract][Full Text] [Related]
2. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S; Harris AL
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
[TBL] [Abstract][Full Text] [Related]
3. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez G; Giuliani A
J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
[TBL] [Abstract][Full Text] [Related]
4. Targeting hypoxia cell signaling for cancer therapy.
Melillo G
Cancer Metastasis Rev; 2007 Jun; 26(2):341-52. PubMed ID: 17415529
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Melillo G
Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
[TBL] [Abstract][Full Text] [Related]
6. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level.
Hubert A; Paris S; Piret JP; Ninane N; Raes M; Michiels C
J Cell Sci; 2006 Aug; 119(Pt 16):3351-62. PubMed ID: 16882692
[TBL] [Abstract][Full Text] [Related]
7. HIF-1alpha and p53: the ODD couple?
Fels DR; Koumenis C
Trends Biochem Sci; 2005 Aug; 30(8):426-9. PubMed ID: 15996866
[TBL] [Abstract][Full Text] [Related]
8. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
9. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer.
Giatromanolaki A; Harris AL
Anticancer Res; 2001; 21(6B):4317-24. PubMed ID: 11908686
[TBL] [Abstract][Full Text] [Related]
10. Activating transcription factor 2 increases transactivation and protein stability of hypoxia-inducible factor 1alpha in hepatocytes.
Choi JH; Cho HK; Choi YH; Cheong J
Biochem J; 2009 Nov; 424(2):285-96. PubMed ID: 19712049
[TBL] [Abstract][Full Text] [Related]
11. Targeting the molecular basis for tumour hypoxia.
Carroll VA; Ashcroft M
Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the hypoxia-inducible factor in cancer and ischemic disease.
Brahimi-Horn MC; Pouysségur J
Biochem Pharmacol; 2007 Feb; 73(3):450-7. PubMed ID: 17101119
[TBL] [Abstract][Full Text] [Related]
13. The hypoxic inducible stress response as a target for cancer drug discovery.
Welsh SJ; Koh MY; Powis G
Semin Oncol; 2006 Aug; 33(4):486-97. PubMed ID: 16890803
[TBL] [Abstract][Full Text] [Related]
14. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
16. When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy.
Ader I; Malavaud B; Cuvillier O
Cancer Res; 2009 May; 69(9):3723-6. PubMed ID: 19383898
[TBL] [Abstract][Full Text] [Related]
17. Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy.
Prabhu V; Guruvayoorappan C
Immunopharmacol Immunotoxicol; 2011 Sep; 33(3):568-75. PubMed ID: 21226555
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization.
Loinard C; Ginouvès A; Vilar J; Cochain C; Zouggari Y; Recalde A; Duriez M; Lévy BI; Pouysségur J; Berra E; Silvestre JS
Circulation; 2009 Jul; 120(1):50-9. PubMed ID: 19546390
[TBL] [Abstract][Full Text] [Related]
20. Non-hypoxic activation of the negative regulatory feedback loop of prolyl-hydroxylase oxygen sensors.
Tug S; Delos Reyes B; Fandrey J; Berchner-Pfannschmidt U
Biochem Biophys Res Commun; 2009 Jul; 384(4):519-23. PubMed ID: 19427832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
